GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (BSP:N1BI34) » Definitions » Cyclically Adjusted Revenue per Share

Neurocrine Biosciences (BSP:N1BI34) Cyclically Adjusted Revenue per Share : R$2.84 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Neurocrine Biosciences Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Neurocrine Biosciences's adjusted revenue per share for the three months ended in Mar. 2024 was R$1.238. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$2.84 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Neurocrine Biosciences's average Cyclically Adjusted Revenue Growth Rate was 29.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 39.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 48.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Neurocrine Biosciences was 74.40% per year. The lowest was -11.70% per year. And the median was -0.50% per year.

As of today (2024-06-05), Neurocrine Biosciences's current stock price is R$36.19. Neurocrine Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was R$2.84. Neurocrine Biosciences's Cyclically Adjusted PS Ratio of today is 12.74.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Neurocrine Biosciences was 125.15. The lowest was 7.31. And the median was 24.53.


Neurocrine Biosciences Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Neurocrine Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Cyclically Adjusted Revenue per Share Chart

Neurocrine Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.06 1.58 2.13 2.67

Neurocrine Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.22 2.31 2.60 2.67 2.84

Competitive Comparison of Neurocrine Biosciences's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PS Ratio falls into.



Neurocrine Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Neurocrine Biosciences's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.238/131.7762*131.7762
=1.238

Current CPI (Mar. 2024) = 131.7762.

Neurocrine Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.039 99.621 0.052
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.032 100.470 0.042
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.012 103.349 0.015
201709 0.108 104.136 0.137
201712 0.176 104.011 0.223
201803 0.130 105.290 0.163
201806 0.203 106.317 0.252
201809 0.322 106.507 0.398
201812 0.266 105.998 0.331
201903 0.292 107.251 0.359
201906 0.373 108.070 0.455
201909 0.476 108.329 0.579
201912 0.515 108.420 0.626
202003 0.597 108.902 0.722
202006 0.799 108.767 0.968
202009 0.748 109.815 0.898
202012 0.656 109.897 0.787
202103 0.679 111.754 0.801
202106 0.743 114.631 0.854
202109 0.800 115.734 0.911
202112 0.901 117.630 1.009
202203 0.792 121.301 0.860
202206 0.998 125.017 1.052
202209 1.027 125.227 1.081
202212 1.073 125.222 1.129
202303 1.128 127.348 1.167
202306 1.096 128.729 1.122
202309 1.218 129.860 1.236
202312 1.235 129.419 1.257
202403 1.238 131.776 1.238

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Neurocrine Biosciences  (BSP:N1BI34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Neurocrine Biosciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=36.19/2.84
=12.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Neurocrine Biosciences was 125.15. The lowest was 7.31. And the median was 24.53.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Neurocrine Biosciences Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences (BSP:N1BI34) Business Description

Traded in Other Exchanges
Address
12780 El Camino Real, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (BSP:N1BI34) Headlines

No Headlines